



**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



Nome/Cognome SHEILA PIVA

ESPERIENZA LAVORATIVA

16/03/2016 – Oggi

Dott.ssa Gabriella Farina – Ospedale Fatebenefratelli e Oftalmico - Milano
Dipartimento di Oncologia e Chemioterapia
Dirigente Medico ex-primo livello a tempo indeterminato

01/08/2013 – 15/03/2016

Dott.ssa Gabriella Farina – Ospedale Fatebenefratelli e Oftalmico - Milano
Dipartimento di Oncologia e Chemioterapia
Dirigente Medico ex-primo livello a tempo determinato

11/06/2012 – 07/10/2012

Dott.ssa Gabriella Farina – Ospedale Fatebenefratelli e Oftalmico - Milano
Dipartimento di Oncologia e Chemioterapia
Incarico di supplenza per dirigente Medico ex-primo livello

Novembre 2009 – Giugno 2012 e Ottobre 2012 - Luglio 2013

Dott.ssa Gabriella Farina – Ospedale Fatebenefratelli e Oftalmico - Milano
U.O. Oncologia
Medico borsista specialista in oncologia

Luglio 2006 –Ottobre 2009

Prof. Paolo Corradini
U.O. Ematologia e Trapianto di midollo allogenico
Medico specializzando

Marzo 2004 - Luglio 2006

Dott.ssa Elena Piazza – Ospedale Luigi Sacco - Milano
U.O. Oncologia
Medico frequentatore

ISTRUZIONE E FORMAZIONE

Novembre 2011- Marzo 2013

Master in Oncologia Toracica
Prof. Giorgio Scagliotti, Ospedale San Luigi, Orbassano (TO)

Marzo 2012

ESO- ESMO Masterclass In Clinical Oncology
Ermatingen, Switzerland

Ottobre 2011

Istituto Oncologico della Svizzera Italiana, Bellinzona, Svizzera.
ESMO Visita a un'Unità di Ricerca Traslazionale

Novembre 2009

Università statale degli studi di Milano
Oncologia medica

Diploma di specializzazione in Oncologia medica

Tesi sperimentale: "Il trapianto allogenico migliora la sopravvivenza nei pazienti con linfoma di Hodgkin ricaduto dopo trapianto autologo".

Luglio 2005

Università degli studi di Milano

Medicina e chirurgia

Laurea in medicina e chirurgia

Tesi sperimentali: "Utilità clinica del marcatore Her-2/neu nelle pazienti con carcinoma mammario".

1998

Cambridge University

Certificate of Proficiency in English

PUBBLICAZIONI SCIENTIFICHE

FULL PAPER

Kasangian AA, Gherardi G, Biagioli E, Torri V, Moretti A, Bernardin E, Cordovana A, Farina G, Bramati A, **Piva S**, Dazzani MC, Paternò E, La Verde NM. The prognostic role of tumor size in early breast cancer in the era of molecular biology. PLoS One. 2017 Dec 6;12(12):e0189127. doi: 10.1371/journal.pone.0189127. eCollection 2017.

Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, **Piva S**, Ceppi L, Broggin M, Marabese M. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217.

Rulli E, Marabese M, **Piva S**, Bonomi L, Caiola E, Ganzinelli M. DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy. Tumori. 2016 Aug 3;102(4):367-75. doi: 10.5301/tj.5000526. Epub 2016 Jul 7.

Ganzinelli M, Rulli E, Caiola E, Chiara Garassino M, Broggin M, Copreni E, **Piva S**, Longo F, Labianca R, Bareggi C, Agnese Fabbri M, Martelli O, Fagnani D, Cristina Locatelli M, Bertolini A, Valmadre G, Pavese I, Calcagno A, Giuseppa Sarobba M, Marabese M. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep. 2015 Nov 17;5:16331. doi: 10.1038/srep16331.

Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, **Piva S**, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggin M, Rulli E. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015 Oct 20;6(32):34014-22. doi: 10.18632/oncotarget.5607.

Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, **Piva S**, Dimaiuta M, La Verde N. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with biphosphonates for bone metastases. J Bone Miner Metab. 2015 Jan;33(1):119-24. doi: 10.1007/s00774-014-0566-x. Epub 2014 Feb 20.
Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, **Piva S**, Moretti A, Dazzani MC, Sburlati P, La Verde N. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev. 2014 Jun;40(5):605-13. doi: 10.1016/j.ctrv.2014.01.003. Epub 2014 Feb 4. Review.

La Verde N, Moretti A, Farina G, Dazzani MC, Gamucci T, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Traverso ES, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, Girelli S, **Piva S**, Di Maio M. Eribulin in cutaneous breast cancer metastasis treatment: clinical activity and symptom control. Future Oncol. 2013 Dec;9(12):1841-8. doi: 10.2217/fon.13.216.

La Verde N, **Piva S**, Ganzinelli M, Farina G, Gherardi G, Girelli S, Bramati A, Del Re L, Damia G. Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin. Future Oncol. 2013 Nov;9(11):1703-9. doi: 10.2217/fon.13.169.

Piva S, Ganzinelli M, Garassino MC, Caiola E, Farina G, Broggin M, Marabese M. Across The Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer. *Curr Pharm Des*. 2014;20(24):3933-43. Review.

Garassino MC, Martelli O, Broggin M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Lancet Oncol. 2013 Sep;14(10):981-8. doi: 10.1016/S1470-2045(13)70310-3. Epub 2013 Jul 22.

Garassino M.C., **Piva S**, La Verde N., Spagnoletti I., Iorno V., Carbone C., Febbraro A., Bianchi A., Bramati A., Moretti A., Ganzinelli M., Marabese M., Gentili M., Torri V., Farina G.

Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

PLoS One. 2013;8(4):e59981. doi: 10.1371/journal.pone.0059981. Epub 2013 Apr 5.

La Verde N, **Piva S**, Colombo F, Borgonovo K, Gramegna G, Girelli S, Dimaiuta M, Galfrascoli E, Battaglia E, Farina G. Lung infiltrates in cancer patients: differentiating metastases from bronchiolitis obliterans organizing pneumonia. *Immunopharmacol Immunotoxicol*. 2013 Feb;35(1):195-7. doi: 10.3109/08923973.2012.733706. Epub 2012 Oct 26.

La Verde N, Moretti A, Bramati A, Bianchi F, Gherardi G, **Piva S**, Girelli S, Pedretti D, Farina G. Multiple myeloma with prostate involvement: a case report. *J Clin Oncol*. 2012 Nov 1;30(31):e306-8. doi: 10.1200/JCO.2012.42.7179. Epub 2012 Sep 10.

La Verde N, Bramati A, Girelli S, **Piva S**, Moretti A, Sburlati P, Mihali D, Farina G. Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report. *Anticancer Drugs*. 2012 Aug;23(7):758-60. doi: 10.1097/CAD.0b013e3283556bbe.

Lurati C, Riva M, Resega R, Mantica C, Garassino MC, Sburlati P, La Verde N, Cinquini M, **Piva S**, Mencacci C, Farina G. A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. *Support Care Cancer*. 2012 Mar;20(3):475-81. doi: 10.1007/s00520-011-1096-x. Epub 2011 Jan 22.

Galfrascoli E, **Piva S**, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V, Muserra G, Farina G, Garassino MC; ORION Collaborative Group. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. *Dig Liver Dis*. 2011 Apr;43(4):286-94. doi: 10.1016/j.dld.2010.10.010. Epub 2010 Dec 13. Review.

Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, **Piva S**, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *Leuk Lymphoma*. 2008 Nov;49(11):2156-62. Doi: 10.1080/10428190802483778.

ABSTRACT, POSTER E REVIEW

La Verde N, Dazzani C, Moretti A, Gamucci K, Borgonovo K, Botta M, Salesi N, Zuradelli M, Pavese I, Barbieri E, Cretella E, Saladino T, Varese P, Addamo G, Ciccarese M, Rispoli AI, Pellegrino A, Mentuccia L, **Piva S**, Farina G, Di Maio M. Activity of eribulin on skin metastases in breast cancer patients. *J Clin Oncol* 31: 2013 (suppl; abstr e12021)

Piva S, Vitali M, Garassino MC. Targeted Therapy in Non-Small Cell Lung Cancer: an Update. *Cancer Chemotherapy Reviews*, 2012, Vol 7, No 3.

La Verde N, Bramati A, **Piva S**, Dazzani MC, Girelli S, Moretti A, Mihali D, Dimaiuta M, Pinto A e Farina G. A prospective mono-institutional study on the impact of a systematic prevention program on the incidence and

outcome of osteonecrosis of the jaw (ONJ) in patients (pts) treated with biphosphonates (B) for bone metastases. *Ann Oncology* (2012), 23 (s9):1585P.

Bramati A, **Piva S**, La Verde N, Girelli S, Cobelli S, Moretti A, Mantica C, Pinto A, Rovej R, Farina G. A long term mono-institutional follow-up of the incidence of osteonecrosis of the jaw (ONJ) with a prevention program in patients treated with biphosphonates (B) for bone metastases. *Tumori* 2012, vol 13, n 3, abs S57.

La Verde N, Bramati A, Bianchi A, Galfrascoli E, Sburlati P, Garassino M, **Piva S**, Torri V, Cinquini M, Farina G. Efficacy of biologic agents (BA) in metastatic, triple-negative breast cancer (TNBC): A systematic review. *J Clin Oncol* 29: 2011 (suppl; abstr e11587).

Piva S, Garassino MC. Novità nel trattamento dei tumori polmonari non microcitomi. *Medical Oncology Progress and Perspectives*, Update 38, 2011.

Piva S, Garassino MC. Trattamento del carcinoma renale metastatico nel paziente dializzato. Esperienze cliniche nel trattamento del carcinoma a cellule renali. *Medicom*, Springer-Verlag, 2011.

Piva S, Mantica C, La Verde N, Bramati A, Mora M, Causarano I, Lacaita G, Piazza E, Martini C, Farina G. A new organizational model in the city of Milan has improved the best setting of care for terminal patients. *Ann Oncol* (2010) 21(s8): viii343.

Cinquini M, Martelli O, Rossi A, **Piva S**, Farina G, Torri V. Meta-analysis of published randomized clinical trials (RCTS) comparing platinum/etoposide (PE) versus platinum/topoisomerase 1 inhibitors (PTIS) regimens for extensive-disease small-cell lung cancer (ED-SCLC). *Ann Oncol* (2010) 21(s8): viii150.

Bramati A, Girelli S, Garassino MC, **Piva S**, La Verde N, Sburlati P, Moretti A, Bianchi A, Celso B, Farina G. Sunitinib-related psoriasis remission in patients affected by advanced clear cell renal cell carcinoma (RCC). *Ann Oncol* (2010) 21(s8): viii398.

Bramati A, Garassino M, Cinquini M, Collovà E, Sburlati P, Califano R, La Verde N, **Piva S**, Farina G, Moretti A, Zucali P. Second-line chemotherapy for malignant pleural mesothelioma: results from a multicenter retrospective analysis. Abstract 1023, *ICACT* 2010.

Piva S, Spina F, Farina L, Doderò A, Milani R, Frungillo N, Morelli M, Montefusco V. Immune mediated cytopenia after reduced intensity allogeneic stem cell transplantation. *Haematologica* 2009; 94(s4):174–175.

Montefusco V, Spina F, Galassi M, Capone F, Farina L, Doderò A, **Piva S**, Morelli M, Ascani L, Corradini P. Preliminary results of topical menthol for Bortezomib-induced peripheral neuropathy. *Haematologica* 2009; 94(s4):89.

Spina F, Farina L, Montefusco V, Carniti C, Morelli M, **Piva S**, Corradini P. Rituximab and donor lymphocyte infusions: an effective salvage treatment for lymphoma patients relapsed after reduced intensity allogeneic stem cell transplantation. *Haematologica* 2009; 94(s4):99–100.

Montefusco V, Spina F, Farina L, Doderò A, Milani R, Frungillo N, Morelli M, **Piva S**, Corradini P. Autologous stem cell transplantation in old multiple myeloma patients. *Haematologica* 2009; 94(s4):206–207.

Spina F, Farina L, Montefusco V, Carniti C, **Piva S**, Morelli M, Corradini P. Efficacy of rituximab and donor lymphocyte infusions as salvage treatment in lymphoma patients relapsed after reduced intensity allogeneic stem cell transplantation. *Haematologica* 2009; 94(s2):61.

Dalu D, Cattaneo MT, Piazza E, **Piva S**, Gambaro A, Tosca N, Gabris A, Filipazzi V, Esani G, Ferrario S, Somma L, Sarnataro C, Zambelli S, Damiani E. Clinical use of the serum marker HER-2/neu in patients with breast cancer. *Annals of Oncology* 2007; vol 18, supp 11.

Milani R, Doderò A, **Piva S**, Testi A, Tarella C, Bandini G, Bernardi M, Gianni AM, Leoni P, Olivieri A, Corradini P. Long-term outcome after reduced-intensity conditioning allogeneic transplantation in therapy-related myelodysplastic syndromes and acute myeloid leukemias. *Haematologica* 2007; 92(s1): 383–4.

Piazza E, Schiavello E, Gambi V, Fasola C, **Piva S**, Cattaneo MT, Filipazzi V, Dalla Vecchia L, Gambaro A, Tosca N, Esani G, Ferrario S, Isabella L, Damiani E. Use of NT-proBNP as a marker of cardio-toxicity during antineoplastic chemotherapy. *Annals of Oncology* 2005; vol 16, supp 7.

Lucini D, Pizzinelli P, Malacarne C, Piva S, Pace F, Pagani M. Qualità percepita ed efficacia della didattica frontale in medicina interna: risultati preliminari e proposta di modello valutativo. 105° Congresso Nazionale della Società Italiana di Medicina Interna, 23-26 ottobre 2004, Palermo